Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „NSCLC“
Suchtreffer
Begriffe & Kennungen
Tecentriq · 4.8 · Use of atezolizumab in the adjuvant NSCLC setting
Eintrag öffnenTepmetko · 4.8 · Table 2: Adverse reactions in patients with NSCLC harbouring METex14 skipping alterations (VISION) System orga
Eintrag öffnenTevimbra · 4.8 · Pneumonitis occurred in 11.2% of patients with NSCLC treated with tislelizumab in combination with chemotherap
Eintrag öffnenVegzelma · 4.8 · In patients with NSCLC excluding predominant squamous histology, all Grade reactions were seen with a frequenc
Eintrag öffnenXalkori · 4.8 · 24 Adult patients with NSCLC All-causality complex renal cysts were experienced by 52 (3%) of 1722 adult patie
Eintrag öffnenXalkori · 4.8 · Across studies in adult patients with either ALK-positive or ROS1-positive advanced NSCLC (N=1722), Grade 3 or
Eintrag öffnenXalkori · 4.8 · Adult patients with NSCLC Across studies in adult patients with either ALK-positive or ROS1-positive advanced
Eintrag öffnenXalkori · 4.8 · Adult patients with NSCLC Across studies in adult patients with either ALK-positive or ROS1-positive advanced
Eintrag öffnenXalkori · 4.8 · Adult patients with NSCLC Drug-induced hepatotoxicity with fatal outcome occurred in 0.1% of 1722 adult patien
Eintrag öffnenXalkori · 4.8 · Adult patients with NSCLC In clinical studies with crizotinib in adult patients with either ALK-positive or RO
Eintrag öffnenXalkori · 4.8 · Adult patients with NSCLC In studies with crizotinib in adult patients with either ALK-positive or ROS1-positi
Eintrag öffnenXalkori · 4.8 · Adult patients with NSCLC Nausea (57%), diarrhoea (54%), vomiting (51%) and constipation (43%) were the most c
Eintrag öffnenXalkori · 4.8 · Adult patients with NSCLC Severe, life-threatening, or fatal ILD/pneumonitis can occur in patients treated wit
Eintrag öffnenXalkori · 4.8 · In clinical studies of adult patients with NSCLC treated with crizotinib, events of gastrointestinal perforati
Eintrag öffnenXalkori · 4.8 · In clinical studies of crizotinib in adult patients with either ALK-positive or ROS1-positive advanced NSCLC,
Eintrag öffnenXalkori · 4.8 · Nervous system effects Adult patients with NSCLC All-causality neuropathy, as defined in Table 9, was experien
Eintrag öffnenXalkori · 4.8 · Summary of the safety profile in adult patients with ALK-positive or ROS1-positive advanced NSCLC
Eintrag öffnenXalkori · 4.8 · Table 9. Adverse reactions reported in crizotinib clinical studies of NSCLC (N=1722) System organ class Very c
Eintrag öffnenXalkori · 4.8 · The data described below reflect exposure to XALKORI in 1669 patients with ALK-positive advanced NSCLC who par
Eintrag öffnenXalkori · 4.8 · The most serious adverse reactions in 1722 patients with either ALK-positive or ROS1-positive advanced NSCLC w
Eintrag öffnen